Hong Kong · Delayed Price · Currency is HKD Zhaoke Ophthalmology Company Description
Zhaoke Ophthalmology Limited operates as an ophthalmic pharmaceutical company in Hong Kong, Mainland China, South Korea, and internationally.
The company develops Cyclosporine A ophthalmic gel for the treatment of dry eye disease (DED); RGN-259, an eye drop indicated for moderate-to-severe DED; CsA/rebamipide ophthalmic gel for anti-inflammation and tear film stabilization; and IC-265 in Phase II clinical trial for the treatment of allergic conjunctivitis.
It also engages in the development of NVK-002, an ophthalmic solution to control or slow myopia progression in children and adolescents; BRIMOCHOL PF and Carbachol PF pupil-modulating eye drops to correct for the loss of near vision associated with presbyopia; TAB014, a clinical-stage bevacizumab-based antibody indicated for wAMD; and PAN-90806 a drug indicated in the treatment of wAMD and DME.
In addition, the company develops ZK002, a protein with a novel mechanism of action to contain inflammation and vascular flood leakage; Bimatoprost, a generic drug used in the treatment of glaucoma; Levobetaxolol HCl, a generic eye drop used in the treatment of glaucoma to lower pressure in the eye; and Travoprost, a prescribed PGAs for open-angle glaucoma.
Further, it is involved in the development of Bimatoprost Timolol for targeting glaucoma; Latanoprost Timolol, a PGA and β blocker combination eye drop targeting glaucoma; Travoprost Timolol, a potential first-to-market generic travoprost timolol; and Latanoprost, a prescribed PGAs for open-angle glaucoma.
The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 276 |
| CEO | Xiaoyi Li |
Contact Details
Address: No. 1 Meide 3rd Road Guangzhou China | |
| Phone | 86 20 3906 2828 |
| Website | zkoph.com |
Stock Details
| Ticker Symbol | 6622 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG989M51017 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Xiaoyi Li Ph.D. | Chief Executive Officer and Executive Chairman of the Board |
| Xiangrong Dai | Chief Operating Officer and Executive Director |
| Dr. Lit Fui Lau | President and Chief Scientific Officer |
| Yang Lei | Group General Counsel |
| Dr. Mauro Bove Ph.D. | Senior Vice President of Corporate Development |
| Jiang Feng | Senior Vice President of Sales and Marketing |
| Guohui Zhang | Senior Vice President of Manufacturing and Logistics |
| Carol Liu | Group Head of Regulatory Affairs |
| Suk Yan Yau CPA | Vice President of Financial Dept. and Company Secretary |